Clinical Trial Update: A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy [Phase 2]

View source ↗

Summary

Phase II study evaluating HLX43 in recurrent/metastatic nasopharyngeal carcinoma patients who failed or were intolerant to second-line therapy; recruitment is o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Nasopharyngeal Carcinoma (NPC) | Phase 2 | Status: RECRUITING